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Abstract
The human immunodeficiency virus (HIV) mutational archive of
proviral DNA was monitored during a 72-week follow-up in 20
multidrug-experienced HIV-1-infected patients treated with a
darunavir/ritonavir-based salvage therapy. At the beginning of the
study, all patients harboured a number of intracellular drug
resistance-associated mutations (RAMs) in peripheral blood
mononuclear cells. In some patients, a significant fluctuation in
the number of RAMs was observed during the observation period.
However, all patients, notwithstanding the presence or the
fluctuation of intracellular RAMs, showed a persistently undetect-
able viraemia. The data suggest that the archived resistant viral
variants change during suppressive therapy, but that the variants
are unable to re-emerge and to affect virological response.
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There are increasing data on the detection of human
immunodeficiency virus (HIV)-1 drug resistance mutations in
proviral DNA, but the modifications of the mutational archive
of proviral HIV-1 DNA during suppressive antiretroviral
therapy (ART) and their role in therapy failure have not been
fully addressed [1–3].
In the present study, a group of multidrug-experienced
patients who, after a further therapy failure, achieved
successful virological suppression with a darunavir/ritonavir-
containing salvage regimen was monitored for 72 weeks.
The aims of this study were to examine the changes in
intracellular drug resistance-associated mutation (RAM) pat-
terns, and to assess the ability of the archived viral variants to
re-emerge during ART.
The study involved 20 consecutive patients belonging to a
larger cohort of HIV-1 patients enrolled in an Early Access
Programme (EAP) of darunavir/ritonavir at the Department of
Clinical Medicine, ‘Sapienza’ University Hospital. The main
characteristics of the patients are summarized in Table 1.
As stated, all individuals were multidrug-experienced, with a
mean treatment time of 17.6  3.6 years, and had failed
several therapeutic regimens. Patients had received a mean of
5.2  2.2 protease inhibitors, and 6.4  2.0 nucleoside
reverse transcriptase inhibitors. Eighteen patients had previ-
ously failed a non-nucleoside reverse transcriptase inhibitor-
based regimen, and 16 subjects had been exposed to
enfuvirtide (T-20). Patients were given a salvage treatment
including darunavir/ritonavir (600/100 mg twice daily) plus an
optimized background therapy according to the results of the
genotypic resistance test, performed just before enrolment in
the EAP. The genotypic sensitivity score ranged from 0 to 2.
The numbers of active antiretroviral drugs included in the
salvage regimen are reported in Table 2. Eighteen to
24 months after viral suppression had been achieved, a
simplification strategy was implemented, and, specifically, 13
patients were switched to raltegravir, reducing the number of
drugs to two (darunavir/ritonavir plus raltegravir).
When included in the study, all patients had received
darunavir/ritonavir-containing therapy for 80 weeks, and their
plasma HIV-1 RNA levels were persistently undetectable
(<50 copies/mL as measured with Versant bDNA; Siemens
Healthcare Diagnostics, Tarrytown, NY, USA).
During 72 weeks of follow-up, all patients maintained
persistently undetectable viral loads (<37 copies/mL as mea-
sured with Versant kPCR; Siemens Healthcare Diagnostics),
with two patients experiencing an isolated blip of viraemia
(<200 copies/mL).
Intracellular drug resistance mutations were examined in
peripheral blood mononuclear cells (PBMCs) at T0 (the
beginning of the observation period) and after 18, 36, 54 and
72 weeks from T0. DNA was extracted from 5 9 106 PBMCs
with the Dneasy Tissue kit (Qiagen, Milan, Italy); to check the
DNA extraction, the b-actin gene was amplified as described
previously [4]. Genotypic resistance tests were performed on
viral DNA with a commercial sequencing method (TruGene
HIV-1 Genotyping kit or Trugene Core Reagents; Siemens
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Healthcare Diagnostics), modified as previously described
[4,5]. RAMs were defined according to the Stanford HIV Drug
Resistance Database (http://hivdb.stanford.edu).
As expected, at T0 all patients showed a high number of
intracellular drug resistance mutations, the mean number of
RAMs being 12 (5.2). Specifically, in the reverse transcriptase
region, the mean number of mutations was 5.0 (2.2), and in
the protease region it was 7.1 (3.6). As expected, no
raltegravir RAMs were detected in the integrase gene. All
mutations were related to the ART regimen previously
received by the patients, and, in most cases, were concordant
with mutations detected in plasma RNA analysed just before
enrolment in the EAP. As shown in Fig. 1, in the majority of
patients a fluctuation in the number of mutations was detected
during the follow-up, and was independent of the treatment
received by patients. Considering the patients as a whole, the
number of RAMs increased in six of 20 patients and decreased
in three of 20 patients. In the remaining patients, although the
number of mutations detected at T0 was similar (2
mutations) to that observed at the end of the analysis, a
fluctuation in the number and/or type of mutations was
detected during the follow-up. Taken together, these findings
suggest that a change in the mutational archive may occur even
in the presence of effective therapy.
Different assumptions can be made to explain the appear-
ance/disappearance of mutations. As suggested by others [6,7],
low-level replication might persist during suppressive ART. In
this study, the plasma HIV-1 RNA levels were persistently
undetectable (<37 copies/mL). Because these methods are not
standardized at the level of viraemia between 1 and 36 copies/
mL, we could not rule out the possibility of the existence of
very low levels of viraemia (from 1 to 36 copies/mL) during
follow-up. It is unlikely that this level of residual viraemia is
responsible for the appearance of new mutations [8,9], but one
can speculate that persistent viral replication of archived
variants may, over time, lead to changes in the mutational
archive.
A low level of replication may also occur in cells located in
sanctuary sites, where drug levels may be suboptimal [10,11].
Furthermore, the modifications of HIV-1 DNA in the muta-
tional archive may result from a redistribution towards the
TABLE 2. Summary of the antiretroviral (ARV) treatment
of the enrolled patients: historical therapies, and the number
of active drugs included in the optimized background therapy
(OBT)
Patients Number of previous ARVs used
Number of active drug
included in the OBT
1 5 PIs, 6 NRTIs, NNRTI, T20 0
2 6 PIs, NNRTI, 7 NRTIs 1
3 6 PIs, 6 NRTIs, 2 NNRTIs, T-20 1
4 6 PIs, 6 NRTIs, 2 NNRTIs, T-20 0
5 3 PIs, 4 NRTIs 1
6 5 PIs, 6 NRTIs, NNRTI, T-20 1
7 4 PIs, NNRTI, 5 NRTIs, T-20 0
8 4 PIs, 6 NRTIs, 2 NNRTIs, T-20 0
9 6 PIs, 6 NRTIs, T-20 1
10 6 PIs, 6 NRTIs, 2 NNRTIs 2
11 6 PIs, 6 NRTIs, 2 NNRTIs, T-20 1
12 4 PIs, 2 NNRTIs, 6 NRTIs 1
13 5 PIs, 2 NNRTIs, 6 NRTIs, T-20 1
14 6 PIs, NNRTI, 7 NRTIs, T-20 1
15 5 PIs, NNRTI, 6 NRTIs, T-20 0
16 5 PIs, NNRTI, 4 NRTIs, T-20 0
17 5 PIs, 2 NNRTIs, 6 NRTIs, T-20 1
18 6 PIs, 6 NRTIs, 2 NNRTIs, T-20 0
19 6 PIs, 7 NRTIs, NNRTI, T-20 1
20 5 PIs, 4 NRTIs, NNRTI, T-20 0
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
Patients with darunavir resistance mutations are reported in bold.
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FIG. 1. Number of mutations detected during follow-up in each
patient. T0, start of the study; T1, 18 weeks after T0; T2, 36 weeks
after T0; T3, 54 weeks after T0; T4, 72 weeks after T0. Genotypic
analysis was performed on all samples available.
TABLE 1. Main characteristics of enrolled patients, including
clinical aspects and CD4+ T-cell counts
Sex (male/female) 19 : 1
Age (years), mean  SD (range) 56  7.6 (44–71)
Risk factor 9 MSM
7 IDA
4 HTR
CDC group 16 C3
4 B3
Years from HIV-1 diagnosis, mean  SD (range) 19.8  4.3 (13–27)
Years of previous ARV therapy, mean  SD (range) 17.6  3.6 (11–25)
CD4+ T-cells/lL nadir, mean  SD (range) 73.3  45.08 (12–146)
CD4+ T-cells/lLa, mean  SD (range) 174.8  83.9 (23–324)
CD4+ T-cells/lL at the end of follow-up,
mean  SD (range)
426.4  161.6 (124–844)
Plasma HIV-1 RNAa (log10 copies/mL), median (range) 4.3 (2.8–5.4)
ARV, antiretroviral therapy; CDC, center for disease control and prevention; HIV,
human immunodeficiency virus; HTR, heterosexual transmission risk; IDA, intra-
venous drug abuse; MSM, men who have sex with men; SD, standard
deviation.aCD4 and HIV-1 RNA values before the start of salvage therapy.
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peripheral blood of ‘drug-resistant’ infected memory CD4+
T-cells trapped in the lymphoid tissue [12].
Finally, we cannot rule out the possibility that, during
follow-up, a decrease in the amount of the dominant archived
viral variants may lead to variation in the detection of
mutations.
We firmly believe that a more realistic scenario is that all of
the above circumstances coexist and contribute, in different
ways and at different times, to the establishment and to the
dynamic of the intracellular drug resistance pattern.
Interestingly, the analysis of protease inhibitor RAMs
revealed that 18 patients had intracellular mutations associated
with darunavir/ritonavir resistance at T0; specifically, according
to REGA rules [13], six of these 18 patients showed genotypic
resistance to darunavir/ritonavir (score of  3.5), eight had
intermediate susceptibility (score of  2 and <3.5), and four
were fully susceptible (score of <2). After 72 weeks of follow-
up, 14 patients had an unchanged intracellular darunavir/
ritonavir genotypic score, and in four patients the genotypic
score changed, owing to loss and/or acquisition of some
darunavir/ritonavir RAMs.
To date, there are no definitive data on the ability of the
archived viral variants to re-emerge after resumption of
therapy. Several authors have suggested that the presence of
drug-resistant strains in proviral compartments may jeopardize
the efficacy of drugs to which the variants are resistant [2,14].
Our findings indicate that, despite the presence of mutations
associated with darunavir/ritonavir resistance, or resistance to
the other drugs that were included in the optimized
background therapy (Table 2), all patients show persistent
suppression of viral replication. As most of the patients were
switched to darunavir/ritonavir plus raltegravir, and as ralte-
gravir has been shown to be highly active in inhibiting the
replication of drug-resistant strains [15], we cannot rule out
the possibility that raltegravir alone is highly active in
controlling the re-emergence of the drug-resistant variants.
However, recently, Fourati et al. demonstrated that HIV
patients showing sustained undetectable viraemia may harbour
a defective viral genome in PBMCs [16], and this could explain
the lack of ability of resistant strains to successfully re-emerge.
Experiments carried out to explore this possibility failed to
detect defective genomes with the reported stop codons in
our population (data not shown).
A limitation of the study is that the population-sequencing
technologies used do not interrogate clones; therefore, we
cannot determine whether mutations are present in different
variants in the population or are colinear within a given
sequence. Because, in the case of darunavir/ritonavir resis-
tance, the total score is the algebraic sum of scores assigned to
each mutation, this aspect could be particularly relevant, but
such an analysis was beyond the scope of this study.
In conclusion, despite the above limitations, we believe that
the results of our study suggest that, in multidrug-resistant
patients treated with salvage therapy, the archived drug-
resistant viral variants may change during suppressive ART but
this does not affect virological success. This observation,
together with findings reported by other authors [17–19],
further support the idea that genotypic resistance tests on
PBMCs do not provide useful information for assessment of
the risk of virological failure.
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